Glycyx Mor, Inc.
Publicly observedSan Francisco, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Francisco | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Glycyx Mor, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | C2B7XPCFTHC7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant19 Sept 2025Publicly observed
NIH SBIR/STTR award: A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)
USD 1,047,803.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant19 Sept 2025Publicly observed
NIH SBIR/STTR award: A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)
USD 1,197,275.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.